Trey Reilly

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Cooley advised Xometry on its offering of $287.5 million aggregate principal amount of 1% convertible senior notes due 2027. Partners Eric Blanchard, Mischi a Marca and Jason Savich led the Cooley team advising Xometry, which provides AI-enabled manufacturing equipment.

Cooley advised CS Disco on its $246.4 million initial public offering of 7,700,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. CS Disco, whose securities now trade on the New York Stock Exchange under the symbol LAW, is the leading provider of software-as-a-service solutions developed by lawyers for lawyers. Partners Nicole Brookshire, Jodie Bourdet and Nicolas Dumont led the Cooley team.

Cooley advised Xometry on its $347.9 million initial public offering of 7,906,250 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Xometry, whose securities now trade on the Nasdaq Global Select Market under the symbol XMTR, is a leading AI-enabled marketplace for on-demand manufacturing. Partners Eric Blanchard, David Peinsipp, Mike Lincoln and Derek Colla led the Cooley team.

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.